Ieq Capital LLC Has $2.42 Million Position in Becton, Dickinson and Company $BDX

Ieq Capital LLC lessened its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 68.4% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 15,985 shares of the medical instruments supplier’s stock after selling 34,613 shares during the period. Ieq Capital LLC’s holdings in Becton, Dickinson and Company were worth $2,419,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BDX. Auto Owners Insurance Co boosted its holdings in Becton, Dickinson and Company by 22,225.2% in the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock valued at $790,079,000 after purchasing an additional 40,528,680 shares during the period. BlackRock Inc. bought a new position in shares of Becton, Dickinson and Company during the 2nd quarter worth about $3,721,533,000. Wellington Management Group LLP raised its position in shares of Becton, Dickinson and Company by 9,056.3% during the third quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier’s stock valued at $979,290,000 after buying an additional 5,174,944 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Becton, Dickinson and Company by 23,219.2% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 4,155,709 shares of the medical instruments supplier’s stock valued at $769,397,000 after buying an additional 4,137,888 shares during the period. Finally, Norges Bank bought a new stake in shares of Becton, Dickinson and Company in the fourth quarter valued at about $734,321,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.5%

Shares of BDX opened at $189.87 on Wednesday. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The stock has a market cap of $52.32 billion, a PE ratio of 57.19, a PEG ratio of 13.44 and a beta of 0.19. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $193.07. The stock has a 50 day simple moving average of $163.37 and a 200-day simple moving average of $160.60.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The firm had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same period in the prior year, the business posted $3.68 earnings per share. The business’s revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, sell-side analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be given a dividend of $1.05 per share. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 126.51%.

Analysts Set New Price Targets

Several research firms have commented on BDX. Bank of America cut their price target on Becton, Dickinson and Company from $177.00 to $170.00 in a report on Friday, June 12th. Royal Bank Of Canada upped their target price on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a research note on Thursday, August 13th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. Citigroup reissued a “buy” rating on shares of Becton, Dickinson and Company in a report on Thursday, August 13th. Finally, Piper Sandler increased their price objective on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Hold” and an average price target of $185.67.

Insider Buying and Selling

In related news, EVP Roland Goette sold 2,438 shares of Becton, Dickinson and Company stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the transaction, the executive vice president directly owned 14,856 shares of the company’s stock, valued at $2,686,559.04. This trade represents a 14.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Michael David Garrison sold 1,100 shares of the business’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the transaction, the executive vice president owned 13,172 shares in the company, valued at approximately $1,918,633.52. This trade represents a 7.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 11,704 shares of company stock worth $1,963,618 in the last quarter. 0.40% of the stock is owned by corporate insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.